Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar Biosciences's gross profit for the
three
months ended in Jun. 2026 was $17.72 Mil. Alamar Biosciences's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $47.15 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Alamar Biosciences had a gross margin of 60.21% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Alamar Biosciences Gross Profit Related Terms
Alamar Biosciences Gross Profit Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Gross Profit Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Gross Profit
8.61
41.71
Alamar Biosciences Quarterly Data
Mar25
Jun25
Mar26
Jun26
Gross Profit
6.39
8.58
14.46
17.72
ALMR vs ESTA, NVCR, BFLY: Gross Profit Comparison
For the Medical Devices subindustry, Alamar Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.15 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Alamar Biosciences (ALMR) has a Gross Profit of $47.15 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Alamar Biosciences and its competitors.
Is Alamar Biosciences' Gross Profit too high?
Alamar Biosciences' current Gross Profit is $47.15 Mil. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Gross Profit compare to ESTA and NVCR?
Alamar Biosciences' Gross Profit of $47.15 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Alamar Biosciences and its competitors. Alamar Biosciences's current Gross Profit is $47.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Gross Profit of $47.15 Mil. The current Gross Profit is $47.15 Mil. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Gross Profit is $47.15 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score
Get the complete analysis for ALMR
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
